Profusa's Groundbreaking Presentation on Oxygen Monitoring Technology
Profusa, Inc. (Nasdaq: PFSA), a pioneering digital health company based in Berkeley, California, is set to present an innovative update on its Lumee™ Oxygen tissue monitoring platform at the prestigious Paris Vascular Insights (PVI) 2025. This significant event will take place from December 11-13, 2025, offering a unique platform for leading vascular professionals and innovators to exchange ideas and advancements in vascular and endovascular surgery.
About the Lumee Technology
The Lumee technology represents a substantial leap in the monitoring of tissue oxygen levels in patients suffering from peripheral artery disease. This cutting-edge system enables comprehensive, real-time measurements of oxygen directly in the body, utilizing an implantable hydrogel sensor. The aim is to provide critical data that informs treatment decisions and improves patient outcomes.
Presentation Details
The presentation, titled “Monitoring Tissue Oxygen Dynamics with a Novel Implantable Hydrogel Sensor in Patients with Peripheral Arterial Disease (PAD),” will be led by Dr. Peter Schneider, a distinguished Professor of Surgery at the University of California, San Francisco. His insights into how Lumee technology integrates into clinical practice are eagerly anticipated. The session is scheduled for December 13, 2025, from 1 PM to 1:40 PM CET.
Vision and Leadership at Profusa
Ben Hwang, Ph.D., the Chairman and CEO of Profusa, emphasizes that this technology is designed not only for clinical environments but also for at-home use, thus empowering patients to manage their health actively. The focus on personalized care through technology is what drives Profusa's mission, enabling healthcare providers to access reliable data that reflects a patient’s true biochemical status.
Significance of the Event
PVI 2025 gathers a global audience of vascular specialists dedicated to advancing the field. Profusa's participation underscores its commitment to innovation in healthcare. By presenting at this significant event, the company aims to contribute valuable knowledge and inspire discussions that could influence the future of vascular treatments.
About Profusa
Profusa is committed to creating a new generation of tissue-integrated sensors designed to continually deliver actionable, medical-grade data. These biosensors are not only innovative but also affordable, allowing a broader patient base to benefit from advanced monitoring solutions. Profusa's vision is to provide a personalized biochemical profile that clinicians can rely on, enhancing patient care and improving health outcomes.
Commitment to Innovation
The company’s strategy is to combine intelligent sensor technology with a robust data platform, aiming to revolutionize how healthcare is delivered and experienced. By focusing on continuous real-time data, Profusa is set to change patient monitoring significantly, bringing a more individualized approach to health management.
Frequently Asked Questions
What is the main focus of Profusa's presentation at PVI 2025?
The presentation focuses on the Lumee technology, which continuously monitors tissue oxygen levels in patients with peripheral artery disease.
Who will present the findings at the conference?
Dr. Peter Schneider, a Professor of Surgery, will present the findings related to the Lumee technology at the event.
When is the presentation scheduled?
The presentation will take place on December 13, 2025, from 1 PM to 1:40 PM CET.
What is the significance of the Lumee technology?
The Lumee technology allows for real-time measurement of tissue oxygen, helping clinicians make informed treatment decisions for their patients.
How does Profusa's technology democratize healthcare?
By providing affordable and innovative monitoring solutions, Profusa makes advanced health data accessible to a wider population, enhancing patient empowerment.
